Zestril ( DrugBank: - )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 1 |
| 67 | 多発性嚢胞腎 | 1 |
| 222 | 一次性ネフローゼ症候群 | 2 |
19. ライソゾーム病
臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-007482-21-GB (EUCTR) | 09/11/2009 | 17/08/2009 | Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study | Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study | Fabry disease with proteinuria. MedDRA version: 9.1;Level: LLT;Classification code 10018058;Term: Gene genetic abnormality MedDRA version: 9.1;Classification code 10037032;Term: Proteinuria | Trade Name: perdix Product Name: perdix Trade Name: Zestoretic 10,20 Product Name: ZESTORIC Trade Name: INNOZIDE Product Name: innozide Trade Name: lisinopril Product Name: lisinopril Trade Name: zestril Product Name: zestril Trade Name: coversyl Product Name: coversyl Trade Name: coversyl PLUS Product Name: coversyl PLUS Trade Name: Accupro Product Name: Accupro Trade Name: Accuretic Product Name: Accuretic Trade Name: lopace Product Name: lopace Trade Name: lopace Product Name: lopace Trade Name: triapin Product Name: triapin& triapin Mite | Salford Royal NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |
67. 多発性嚢胞腎
臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-003182-16-GB (EUCTR) | 26/08/2005 | 29/07/2005 | Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs. | Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs. | Polycystic kidney disease | Trade Name: CARDURA Product Name: DOXAZOSIN Trade Name: MONOCOR Product Name: BISOPROLOL Trade Name: ZESTRIL Product Name: LISINOPRIL Trade Name: ISTIN Product Name: AMLODIPINE Trade Name: AMIAS Product Name: CANDESARTAN Trade Name: APRINOX Product Name: BENDROFLUMETHIAZIDE | Addenbrooke's Hospital Trust | NULL | Not Recruiting | Female: yes Male: yes | 42 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |
222. 一次性ネフローゼ症候群
臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-004469-40-BE (EUCTR) | 12/05/2006 | 05/12/2005 | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy | Membranous Nephropathy | Trade Name: Neoral Product Name: Neoral Trade Name: zestril Product Name: zestril | Hopital Erasme | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Belgium | |||
| 2 | EUCTR2005-004460-22-BE (EUCTR) | 12/05/2006 | 05/12/2005 | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. | focal and segmental glomerulosclerosis | Trade Name: Neoral Product Name: Neoral Trade Name: Medrol Product Name: Medrol Trade Name: zestril Product Name: zestril | Hopital Erasme | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Belgium |